| Autor: |
Dalle Carbonare L; Department of Engineering for Innovative Medicine, University of Verona, 37134 Verona, Italy., Minoia A; Department of Engineering for Innovative Medicine, University of Verona, 37134 Verona, Italy., Vareschi A; Department of Engineering for Innovative Medicine, University of Verona, 37134 Verona, Italy., Piritore FC; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy., Zouari S; Department of Engineering for Innovative Medicine, University of Verona, 37134 Verona, Italy., Gandini A; Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 37134 Verona, Italy., Meneghel M; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy., Elia R; Department of Medicine, University of Verona, 37134 Verona, Italy., Lorenzi P; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy., Antoniazzi F; Department of Surgery, Dentistry, Paediatrics and Gynaecology, University of Verona, 37134 Verona, Italy., Pessoa J; Department of Medical Sciences and Institute of Biomedicine-iBiMED, University of Aveiro, 3810-193 Aveiro, Portugal., Zipeto D; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy., Romanelli MG; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy., Guardavaccaro D; Department of Biotechnology, University of Verona, 37134 Verona, Italy., Valenti MT; Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy. |
| Abstrakt: |
Overexpression of the Runt-related transcription factor 2 ( RUNX2 ) has been reported in several cancer types, and the C-X-C motif chemokine receptor 4 ( CXCR4 ) has an important role in tumour progression. However, the interplay between CXCR4 and RUNX2 in melanoma cells remains poorly understood. In the present study, we used melanoma cells and a RUNX2 knockout ( RUNX2 -KO) in vitro model to assess the influence of RUNX2 on CXCR4 protein levels along with its effects on markers associated with cell invasion and autophagy. Osteotropism was assessed using a 3D microfluidic model. Moreover, we assessed the impact of CXCR4 on the cellular levels of key cellular signalling proteins involved in autophagy. We observed that melanoma cells express both RUNX2 and CXCR4 . Restored RUNX2 expression in RUNX2 KO cells increased the expression levels of CXCR4 and proteins associated with the metastatic process. The protein markers of autophagy LC3 and beclin were upregulated in response to increased CXCR4 levels. The CXCR4 inhibitor WZ811 reduced osteotropism and activated the mTOR and p70-S6 cell signalling proteins. Our data indicate that the RUNX2 transcription factor promotes the expression of the CXCR4 chemokine receptor on melanoma cells, which in turn promotes autophagy, cell invasiveness, and osteotropism, through the inhibition of the mTOR signalling pathway. Our data suggest that RUNX2 promotes melanoma progression by upregulating CXCR4 , and we identify the latter as a key player in melanoma-related osteotropism. |
